SCHEMBL3528630

SCHEMBL3528630

CC(C)N1C(=O)NC(c2ccccc2)c2cc3c(cc21)OC(F)(F)O3

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.38
HDAC4 P56524 1/20 0.34
LMNA P02545 3/20 0.34
ADORA3 P0DMS8 1/20 0.34
TDP1 Q9NUW8 1/20 0.33
AR P10275 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CG P48736 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
GPR183 P32249 1/20 0.32
MEN1 O00255 4/20 0.32
KMT2A Q03164 4/20 0.32
USP2 O75604 1/20 0.32
MAPT P10636 2/20 0.32
CFTR P13569 1/20 0.32
ATM Q13315 1/20 0.32
S1PR1 P21453 1/20 0.32
S1PR3 Q99500 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11487326 0.84 SMN1; SMN2 (0.40) BRD4LMNAADORA3MEN1KMT2A
SCHEMBL3522132 0.84 ALDH1A1 (0.43) LMNATDP1MEN1KMT2AMAPT
SCHEMBL11818360 0.78 BRD4 (0.37) BRD4LMNAADORA3TDP1PIK3CA
SCHEMBL11784017 0.78 BRD4 (0.37) BRD4LMNAADORA3TDP1AR
SCHEMBL11815335 0.78 BRD4 (0.37) BRD4LMNAADORA3TDP1PIK3CA
SCHEMBL11785549 0.75 MGLL (0.44) LMNARAB9AMEN1KMT2AMAPT
SCHEMBL3528633 0.75 BRD4 (0.36) BRD4LMNAADORA3TDP1AR
SCHEMBL11487427 0.75 ALDH1A1 (0.39) BRD4LMNAADORA3TDP1MEN1
SCHEMBL11785818 0.75 TDP1 (0.41) LMNATDP1MEN1KMT2AMAPT
SCHEMBL11872481 0.74 MAPT (0.45) LMNATDP1NPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7652006-B2 For therapy and prophylaxis of neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, for ameliorating neurodegenerative diseases EURO-CELTIQUE S.A. (LU) 2010-01-26 US disclosed
US-20040162299-A1 Substituted quinazolines and analogs and the use thereof EURO-CELTIQUE, S.A. 2004-08-19 US disclosed
US-6765006-B2 ANTAGONISTS OF AMINO-3-HYDROXY-5-METHYLISOXAZOLE-4-PROPIONIC ACID (AMPA) IONOTROPIC RECEPTORS; NEURODEGENERATIVE, ALZHEIMER'S, AND HUNTINGTON'S DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; SCHIZOPHRENIA, EXCITATORY AMINO ACID DEFICIENCY EURO-CELTIQUE S.A. (LU) 2004-07-20 US disclosed
EP-1066039-A4 SUBSTITUTED QUINAZOLINES AND ANALOGS AND THE USE THEREOF COCENSYS INC (US) 2003-02-26 EP disclosed
US-20030033089-A1 Substituted quinazolines and analogs and the use thereof EURO-CELTIQUE S.A. 2003-02-13 US disclosed
EP-1066039-A1 SUBSTITUTED QUINAZOLINES AND ANALOGS AND THE USE THEREOF Cocensys, Inc. (US) 2001-01-10 EP disclosed
WO-1999044612-A1 SUBSTITUTED QUINAZOLINES AND ANALOGS AND THE USE THEREOF COCENSYS, INC. (US) 1999-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162299-A1 Substituted quinazolines and analogs and the use thereof CHRNA7, CHRNA2, CHRNA10 BRD4 2086/4885HDAC4 3051/4885LMNA 1204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.